文献速递癫痫

辅助性塞诺氨酯治疗未控制局灶性发作患者的开放标签扩展研究长期疗效与安全性

Long-term Efficacy and Safety From an Open-Label Extension of Adjunctive Cenobamate in Patients With Uncontrolled Focal Seizures.
PubMed 文献 · Neurology · 2022-09-05

本研究为随机双盲安慰剂对照研究的开放标签扩展,纳入355例未控制局灶性发作患者,接受塞诺氨酯(CNB)辅助治疗,中位暴露53.9个月。结果显示中位发作频率降低逐6个月间隔增加至43-48个月的76.1%,24个月保留率71%,未发现新安全性问题。

要点

  • CNB辅助治疗在48个月内维持疗效,43-48个月中位发作频率降低76.1%。
  • 24个月保留率71%,因不良事件停药比例7.6%。
  • 严重不良事件发生率20.3%,未发现新安全性问题。

核心结论

  • CNB治疗48个月内长期疗效持续,包括100%和≥90%发作减少,24个月保留率71%,未发现新安全性问题,结果证实双盲研究并支持潜在长期临床获益。

研究设计与样本

  • 随机双盲安慰剂对照研究的开放标签扩展(OLE),纳入完成18周双盲研究的18-70岁局灶性发作患者(n=360),OLE安全性人群355例,改良意向治疗人群354例。

主要发现

  • 截至2019年7月,58.9%(209/355)患者继续CNB治疗,141例停药,其中因疗效不足停药16.6%(59/355),因患者退出停药8.7%(31/355),因不良事件停药7.6%(27/355)。
  • OLE暴露中位持续时间53.9个月(范围1.1-68.7个月),12、24、36、48个月保留率分别为83%、71%、65%、62%。
  • 中位发作频率较基线降低随每个6个月OLE间隔增加,至43-48个月达76.1%。
  • 在观察到的患者中,>36-48个月期间16.4%(36/220)达到100%发作减少,39.1%(86/220)达到≥90%发作减少;在初始OLE改良意向治疗人群中,10.2%(36/354)达到100%,24.3%(86/354)达到≥90%。
  • 不良事件包括头晕、嗜睡、疲劳和头痛,严重不良事件发生率20.3%(72/355)。

关键数值与推荐

  • CNB目标剂量300 mg/d,最小/最大50/400 mg/d。
  • 口服CNB 50-400 mg/d作为辅助治疗对既往接受1-3种抗癫痫药物治疗的未控制局灶性发作患者长期管理有效(Class IV证据)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: To evaluate long-term efficacy (percent seizure frequency reduction and responder rates), safety, and tolerability of adjunctive cenobamate (CNB) in an open-label extension (OLE) of the randomized, double-blind, placebo-controlled study. METHODS: Patients (aged 18-70 years) with uncontrolled focal seizures despite treatment with 1-3 antiseizure medications who completed the 18-week double-blind study (n = 360) could enter the OLE, where they underwent a 2-week blinded conversion to CNB (target dose, 300 mg/d; min/max, 50/400 mg/d). RESULTS: Three hundred fifty-five patients were included in the OLE safety population (265 originally randomized to CNB, 90 originally randomized to placebo), and 354 were included in the OLE modified intent-to-treat population. As of July 2019, 58.9% of patients (209/355) were continuing CNB treatment and 141 had discontinued, including 16.6% (59/355) because of lack of efficacy, 8.7% (31/355) because of withdrawal by patient, and 7.6% (27/355) because of adverse events. The median (range) duration of OLE exposure was 53.9 (1.1-68.7) months. Retention rates at 12, 24, 36, and 48 months were 83%, 71%, 65%, and 62%, respectively. Median percent seizure frequency reduction over baseline increased with each 6-month OLE interval, up to 76.1% at months 43-48. Among observed patients, 16.4% (36/220) achieved 100% and 39.1% (86/220) achieved ≥90% seizure reduction during >36-48 months. Among the initial OLE modified intent-to-treat population, 10.2% of patients (36/354) achieved 100% and 24.3% (86/354) achieved ≥90% seizure reduction during >36-48 months. Similar to the double-blind study, adverse events (AEs) included dizziness, somnolence, fatigue, and headache. Serious AEs occurred in 20.3% of patients (72/355). DISCUSSION: Long-term efficacy, including 100% and ≥90% seizure reduction, was sustained during 48 months of CNB treatment, with 71% retention at 24 months. No new safety issues were identified. These results confirm the findings of the double-blind study and support the potential long-term clinical benefit of CNB. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that oral CNB 50-400 mg/d is effective as an adjunctive treatment for the long-term management of patients with uncontrolled focal seizures previously treated with 1-3 ASMs. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov NCT01866111 (clinicaltrials.gov/ct2/show/results/NCT01866111).

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Klein P, Aboumatar S, Brandt C, et al. Long-term Efficacy and Safety From an Open-Label Extension of Adjunctive Cenobamate in Patients With Uncontrolled Focal Seizures. Neurology. 2022. PMID: 35705501. doi:10.1212/WNL.0000000000200792

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。